These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26745255)

  • 1. Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes.
    Manell H; Staaf J; Manukyan L; Kristinsson H; Cen J; Stenlid R; Ciba I; Forslund A; Bergsten P
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1181-9. PubMed ID: 26745255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes.
    Pixner T; Chaikouskaya T; Lauth W; Zimmermann G; Mörwald K; Lischka J; Furthner D; Awender E; Geiersberger S; Maruszczak K; Forslund A; Anderwald CH; Cadamuro J; Weghuber D; Bergsten P
    Front Endocrinol (Lausanne); 2024; 15():1368570. PubMed ID: 39027470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose tolerance status in 510 children and adolescents attending an obesity clinic in Central Italy.
    Brufani C; Ciampalini P; Grossi A; Fiori R; Fintini D; Tozzi A; Cappa M; Barbetti F
    Pediatr Diabetes; 2010 Feb; 11(1):47-54. PubMed ID: 19460122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease.
    Nathanson D; Zethelius B; Berne C; Holst JJ; Sjöholm A; Nyström T
    Diabetologia; 2010 Feb; 53(2):277-80. PubMed ID: 19936703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus.
    da Silva RC; Miranda WL; Chacra AR; Dib SA
    J Diabetes Complications; 2007; 21(2):84-92. PubMed ID: 17331856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose.
    Tutuncuoğlu P; Saraç F; Saygili F; Ozgen AG; Yilmaz C; Tüzün M
    Acta Diabetol; 2008 Sep; 45(3):151-6. PubMed ID: 18496644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.
    Stenlid R; Cerenius SY; Wen Q; Aydin BK; Manell H; Chowdhury A; Kristinsson H; Ciba I; Gjessing ES; Mörwald K; Gomahr J; Heu V; Weghuber D; Forslund A; Bergsten P
    Front Endocrinol (Lausanne); 2023; 14():1293093. PubMed ID: 38027106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Glucagon and GLP-1 Responses to Oral Glucose in Children and Adolescents With Obesity and Insulin Resistance.
    Stinson SE; Fernández de Retana Alzola I; Brünner Hovendal ED; Lund MAV; Fonvig CE; Holm LA; Jonsson AE; Frithioff-Bøjsøe C; Christiansen M; Pedersen O; Ängquist L; Sørensen TIA; Holst JJ; Hartmann B; Holm JC; Hansen T
    J Clin Endocrinol Metab; 2024 May; 109(6):1590-1600. PubMed ID: 38087928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action.
    Faerch K; Vaag A; Holst JJ; Glümer C; Pedersen O; Borch-Johnsen K
    Diabetologia; 2008 May; 51(5):853-61. PubMed ID: 18317726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and impaired glucose tolerance in obese children and adolescents referred to a tertiary-care center in Israel.
    Shalitin S; Abrahami M; Lilos P; Phillip M
    Int J Obes (Lond); 2005 Jun; 29(6):571-8. PubMed ID: 15889115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism.
    Adams E; Genter P; Keefe E; Sandow K; Gray V; Rotter JI; Chen YI; Ipp E
    Diabetes Res Clin Pract; 2018 Jan; 135():185-191. PubMed ID: 29155153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review.
    Huber H; Schieren A; Holst JJ; Simon MC
    Am J Clin Nutr; 2024 Mar; 119(3):599-627. PubMed ID: 38218319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.
    Laakso M; Zilinskaite J; Hansen T; Boesgaard TW; Vänttinen M; Stancáková A; Jansson PA; Pellmé F; Holst JJ; Kuulasmaa T; Hribal ML; Sesti G; Stefan N; Fritsche A; Häring H; Pedersen O; Smith U;
    Diabetologia; 2008 Mar; 51(3):502-11. PubMed ID: 18080106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
    Orskov C; Jeppesen J; Madsbad S; Holst JJ
    J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
    Henkel E; Gallo S; Siegert G; Koehler C; Hanefeld M
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):327-34. PubMed ID: 17473573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.